BioSpace News Archive

Drug Development

New Hope for Sickle Cell Disease Patients as FDA Approves Chiesi’s Ferriprox

The U.S. FDA approved Chiesi Global Rare Diseases’ Ferriprox for treatment of transfusional iron overload caused by sickle cell disease (SCD) or other anemias in adults and children ages three years and older. This approval expands the use of the drug for patients with SCD or other anemias.

May 3, 2021
·
3 min read
·
Mark Terry
Drug Development

The Seven Stages of Alzheimer’s Disease Explained

There are seven stages of Alzheimer’s disease, and understanding each stage is a useful aid. This article will help you understand each stage properly.

May 3, 2021
·
5 min read
·
Lorenzo Soliman
Business

Astellas Pulls the Plug on R&D Partnership with Cytokinetics

One year after Astellas and California-based Cytokinetics extended an agreement to develop Skeletal Sarcomere Activators, the Japanese pharma company is walking away from the deal.

May 3, 2021
·
2 min read
·
Alex Keown
FDA

AstraZeneca Celebrates a First as FDA Approves Farxiga for Chronic Kidney Disease

The regulatory nod marks the first time the FDA approved an SGLT2 inhibitor for the treatment of CKD regardless of diabetes status.

May 3, 2021
·
2 min read
·
Alex Keown
Business

Already on Fast Track, Aceragen Launches with $35 Million and Farber Disease Drug

Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.

May 3, 2021
·
2 min read
·
Kate Goodwin
Business

Relay Therapeutics Appoints Key Leadership Members Following Acquisition

Clinical-stage precision medicine company Relay Therapeutics has brought two new senior level management team members into the fold, including Tara O’Meara and Charles Ferté.

May 3, 2021
·
3 min read
·
Brandon May
Drug Development

A Whole New Era Begins as Roivant and Montes Archimedes Merge in Cash-Rich SPAC

Roivant Sciences is combining with Montes Archimedes Acquisition Corp (MAAC). Once the deal is closed, outstanding shares and warrants of MAAC will be traded for newly issued shares and warrants of the company.

May 3, 2021
·
3 min read
·
Mark Terry
Six Dementia Patients Received Controversial Gene Therapy Injection in Mexico, BioVia Says

If actually administered to these patients, this could represent the first recorded attempt to manage dementia that uses an injectable gene therapy technique.

May 3, 2021
·
3 min read
·
Brandon May
BioMidwest

AIM ImmunoTech CEO Thomas K. Equels Participates in Fireside Chat with Ascendiant Capital Markets Analyst Ed Woo

AIM ImmunoTech Inc. announces that Thomas K. Equels, CEO of AIM ImmunoTech, participated in a ‘Fireside Chat’ video interview with Ed Woo, Director of Research & Senior Analyst at Ascendiant Capital Markets.

May 3, 2021
·
3 min read
Deals

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Positioned as Leader in Emerging Psychedelic Therapeutics Market through Robust IP Portfolio, Novel Clinical Trials and Evolving Proprietary Technology

May 3, 2021
·
10 min read